bovine serum and non-essential amino acids of modified Eagle's medium (MEM) at 37°C in a humidified atmosphere of 5% CO 2 in air (Goto et al, 1994 (Goto et al, , 1996 . The cell lines were kindly supplied from the Japanese Cancer Research Resources Bank (Tokyo, Japan).
Assay of cell growth
The cells were seeded at a concentration of 2 × 10 4 ml -1 in a multidish (Nunc, Roskilde, Denmark). After culture with or without the test compounds for 7 days, viable cells were examined by MTT assay (Goto et al, 1994) . Briefly, 100 µl of MTT solution (5 mg ml -1 in PBS) were added to each well. After incubation with MTT for 4 h, the cells were centrifuged at 1000 g for 10 min. The precipitates were dissolved in 1 ml of DMSO and their absorptions at 560 nm were determined.
Assay of the cumulative cell number
The cell density of untreated cells was kept at 1-10 × 10 5 ml -1 to maintain continuous logarithmic growth. The cells were collected by treatment with 0.1% trypsin-0.04% EDTA (GIBCO, Grand Island, NY, USA) for 5 min with gentle shaking, and were transferred every 3 days. The cell density of the treated cells was kept at 3-8 × 10 5 ml -1 to maintain cells in growing phase, and transferred every 3 or 6 days by the trypsinization. The treatment with trypsin did not affect the cell morphology and adhesiveness. The cell number was counted with a Coulter Counter (Model ZBI; Coulter Electronics, Hialeah, FL, USA). The cumulative cell number was calculated from the counts and dilution used when feeding the culture.
Assay of alkaline phosphatase activity
Alkaline phosphatase activity is a marker for the maturation of type II pneumocytes and is not expressed in other alveolar cells (Edelson et al, 1988; McCormick et al, 1995) . Cells were washed twice with cold PBS, resuspended to a cell density of 10 7 cells ml -1 of cold distilled water, and sonicated for 10 s. The reaction mixture contained 50 mM glycine-NaOH (pH 10.5), 0.5 mM magnesium chloride, 4.2 mM p-nitrophenyl phosphate, and the cell lysate in a total volume of 0.4 ml. The incubation was allowed to proceed for 60 min at 37°C, and the reaction was then stopped by adding of 1 ml of 0.1 M NaOH. The absorbance of p-nitrophenol was determined at 410 nm to calculate enzyme activity.
Cell cycle analysis
The cell cycle was analysed using propidium iodide-stained nuclei. Samples of 2 × 10 6 cells were harvested at the time points indicated, washed in ice-cold PBS, fixed by the addition of 100% ethanol and left for 30 min on ice. The cell pellet was washed and suspended in 200 µl of 1.12% sodium citrate containing RNase A (250 µg ml -1 ) for 30 min at room temperature. Thereafter, the cells were stained with 50 µg ml -1 of propidium iodide in the presence of 1.12% sodium citrate and analysed in a fluorescence-activated cell sorter.
Western blot analysis of Rb protein
Cells were washed once with cold PBS, lysed by sonication for 30 s at a concentration of 2 × 10 7 cells ml -1 in sample buffer, and then resolved on 7.5% sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) as described by Laemmli (1970) . The proteins were transferred electrophoretically from the gel to an Immobilon-P membrane (Millipore) and immunoblotted with anti-Rb protein (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The proteins were quantified by an enzyme-linked immunosorbent assay as described previously (Kanatani et al, 1993) .
Transplantation of lung carcinoma cells into nude mice
Female athymic nude mice with a BALB/c genetic background were supplied by CLEA Japan (Tokyo, Japan). The in vivo experiments were performed in accordance with the guidelines of our institute (Guide for Animal Experimentation, Saitama Cancer Center). Mice were inoculated subcutaneously (s.c.) with 10 6 EBC-1 or PC9 cells. Mice were given a daily intraperitoneal (i.p.) injection of 0.2 ml of PBS including prednisolone (300 mg kg -1 ) and/or peroral administration of vesnarinone (5 mg kg -1 ), with the first injection given 4 days after the inoculation of tumour cells. Tumour size was measured with vernier calipers every day. Statistical analysis was performed using Student's t-test.
RESULTS

Combined effects of vesnarinone and Dex on the growth of lung carcinoma cell lines
To measure the growth-inhibitory effects of drugs on lung carcinoma cells, the number of viable cells was determined by the MTT assay after 7 days of exposure to various concentrations of drugs. The growth-inhibitory effects of drugs were examined by determining the concentrations of drugs required to reduce the cell number to one-half that of untreated cells (IC 50 ). Vesnarinone inhibited the growth of lung carcinoma cells in a dose-dependent manner, and the IC 50 of vesnarinone in squamous cell carcinoma LK2 cells was lower than 10 µg ml -1 . However, the growth of the other NSCLC cells was less sensitive, and the respective IC 50 s were more than 20 µg ml -1 (IC 50 : 23.4, 21.3, 29.7 and 30 .6 µg ml -1 in EBC-1, PC9, ABC-1 and A549 cells respectively). Vesnarinone is effective when administered perorally, and the serum level of vesnarinone can be obtained up to 30 µg ml -1 (Miyamoto and Sasabe, 1984; Taira et al, 1984) . These results suggest that treatment with vesnarinone alone is clinically effective in only a limited number of cases of NSCLC. Next, we examined the growth-inhibitory effect of various compounds in combination with vesnarinone. Of the compounds tested, Dex more than additively enhanced the vesnarinoneinduced inhibition of the growth of lung carcinoma EBC-1 cells (Figure 1 ). To determine the structure required for the growth inhibition, the effect of various steroids was examined. The growth inhibition in the presence of vesnarinone was closely correlated with glucocorticoid activity (Table 1 ). The growth-inhibitory effect of vesnarinone was not enhanced by retinoic acid (10 -9 -10 -6 M), 1 α, 25-dihydroxyvitamin D 3 (10 -9 -10 -5 M), sodium butyrate (0.1-2.5 mM), interferon-α (1-3000 IU ml -1 ), actinomycin D Cells were treated with various steroids in the presence or absence of 10 µg ml -1 vesnarinone for 7 days, and the number of viable cells was determined by MTT assay. Data represent means from three experiments ± s.d.
Cell number (× 10 The effect of the time of the addition of Dex or vesnarinone on growth inhibition was examined. Pretreatment with Dex did not affect the growth-inhibitory activity of vesnarinone plus Dex, and the delayed addition of Dex also did not affect growth inhibition (data not shown). Table 2 indicates that simultaneous treatment is the most effective to evoke the synergistic effect of vesnarinone and Dex.
The effect of continuous treatment with 10 µg ml -1 of vesnarinone and 2 × 10 -8 M Dex added simultaneously on the proliferation of EBC-1 cells was examined for 24 days. The cell density was kept at 1-10 × 10 5 ml -1 to maintain cells in the growing phase, and the cumulative cell number was calculated from the counts and dilution used when feeding the culture. Continuous treatment with 10 µg ml -1 of vesnarinone or 2 × 10 -8 M Dex only slightly inhibited the growth of EBC-1 cells. However, combined treatment with vesnarinone and Dex caused significant growth inhibition (Figure 3) . When the cells were treated for 18 days, and then washed and cultured without the drugs, cell growth was greatly inhibited at day 24, indicating that the growth-inhibitory effect of vesnarinone and Dex was irreversible in long-term culture. These results suggest that the combined treatment has therapeutic value in the chemotherapy of some lung cancers. Since alkaline phosphatase activity is a marker for the maturation of type II pneumocytes (Edelson et al, 1988; McCormick et al, 1995) , we measured the effect of Dex and vesnarinone on alkaline phosphatase activity in EBC-1, ABC-1 and PC9 cells. Dex significantly induced alkaline phosphatase activity in the cells, as in a previous report that Dex induces alkaline phosphatase activity in A549 cells (McCormick et al, 1995) . Vesnarinone alone did not induce enzyme activity in the cells, but did significantly enhance the Dex-induced alkaline phosphatase activity in EBC-1 ( Figure  5A ), ABC-1 and PC9 cells ( Figure 5B ).
Cell cycle analysis of EBC-1 cells treated with vesnarinone and Dex
To understand the nature of the joint action of vesnarinone and Dex on the proliferation of EBC-1 cells, we exposed the cells to 10 µg ml -1 of vesnarinone and 2 × 10 -8 M Dex, and then measured the cell cycle distribution after 4 days ( Figure 6 ). This treatment induced growth arrest of the cells at the G 0 -G 1 phase. There were no appreciable apoptotic cells in a culture incubated with vesnarinone and Dex at 7 days. The G 1 arrest in cells treated with vesnarinone plus Dex was more prominent than that in cells cultured in serum-free medium or under confluent conditions (Table 3) .
Dephosphorylation of Rb protein in EBC-1 cells treated with vesnarinone and Dex
A reasonable hypothesis is that arrest of the cell cycle in G 1 was caused by dephosphorylation of Rb protein, whereas the transient G 2 block was independent of Rb protein dephosphorylation (Weinberg, 1995) . Phosphorylation of Rb protein of EBC-1 cells treated with vesnarinone and Dex was analysed by Western blotting using anti-Rb protein monoclonal antibody (Figure 7) . In untreated cells, Rb protein was hyperphosphorylated and migrated slower, while Rb protein was under-phosphorylated and migrated faster in cells treated with vesnarinone and Dex. Phosphorylation began to decrease after 24 h of treatment. Dex+Ves 97.1 ± 9.4 0 2.9 ± 0.3 EBC-1 cells were incubated with or without 20 µg ml -1 of vesnarinone (Ves) in the presence or absence of 2 × 10 -8 M Dex for 7 days. Cells were cultured at a cell density below 3 × 10 5 ml -1 in 10% serum-containing medium (rapidly growing cells) or in serum-free medium (serum-free) for 4 days. Means ± s.d. of three determinations.
Effect of vesnarinone and prednisolone on the in vivo growth of EBC-1 cells as xenografts
The in vitro studies described above suggested that combined treatment with vesnarinone and glucocorticoid should be more effective therapeutically than treatment with vesnarinone or glucocorticoid alone. Although Dex was the most potent steroid tested in the in vitro studies, preliminary results indicated that prednisolone was more effective than Dex in the in vivo experiments. Therefore, we used prednisolone for the further in vivo experiments. The combined treatment significantly inhibited the growth of EBC-1 cells as xenografts (Figure 8 ). At day 20 after the inoculation of tumour cells, the mean tumour volumes of untreated, prednisolone-, vesnarinone-and prednisolone plus vesnarinonetreated nude mice were 1.82 ± 0.12, 1.32 ± 0.16, 0.98 ± 0.13, and 0.36 ± 0.11 cm 3 (± s.d.) respectively. These results indicate that the combination of vesnarinone and prednisolone is more effective therapeutically than vesnarinone or prednisolone alone, and the anti-tumour effect of the combined treatment was statistically significant (P < 0.01). The combined treatment was also effective in xenografts of lung carcinoma PC9 cells (Figure 8 ).
DISCUSSION
Glucocorticoid receptor is widely distributed in human tissues, but receptor activation and regulation are tissue-specific. Glucocorticoids accelerate the appearance of pulmonary surfactant in developing mammalian fetal lungs (Liggins, 1969; DeLemos et al, 1970; Liggins and Howie, 1972) , and hydrocortisone inhibits the rate of mitosis in fetal rabbit lung (Jones et al, 1978) . Glucocorticoids have slight growth-inhibitory effects on some NSCLC cells (Kikkawa et al, 1971; Mattern et al, 1985; McLean et al, 1986) , suggesting that lung cancer may be influenced by glucocorticoid therapy.
Growth of human lung alveolar carcinoma A549 cells is dosedependently inhibited by glucocorticoids, and this growth inhibition is associated with an induction of differentiated function, although the differentiation of lung cancer cells has not been well characterized (Kikkawa et al, 1971; Mattern et al, 1985; McCormick et al, 1995) . Dex induced morphological changes as well as alkaline phosphatase activity in EBC-1 cells, and the same concentrations were effective in combination with vesnarinone, suggesting that these phenotypic changes were partly associated with the sensitization of EBC-1 cells to vesnarinone. Other glucocorticoids were also effective in inhibiting growth in combination with vesnarinone (Table 1 ). The growth-inhibitory effect of Dex plus vesnarinone was observed in all of the NSCLC cells tested. A significant incidence of specific, high-affinity receptors for glucocorticoids is present in NSCLC (Chaudhuri et al, 1982; Beattie et al, 1985; Hofmann et al, 1995) . The growth of approximately one-third of the NSCLC cell lines was inhibited by Dex, although the growth-inhibitory effect was modest in most of the cell lines (Hofmann et al, 1995) . Glucocorticoids can be administered to patients with NSCLC with tolerable side-effects, although the steroids alone have no anticancer effect in lung cancer patients. Glucocorticoids more than additively enhanced vesnarinoneinduced growth inhibition. Therefore, treatment with glucocorticoids in combination with vesnarinone may be a strategy for treating lung cancer with low sensitivity to conventional chemotherapy.
Cyclin-dependent kinase-mediated phosphorylation of Rb protein is prevented by cyclin-dependent kinase inhibitors such as p21 (WAF1/CIP1/SDI1) (Weinberg, 1995) . Therefore, we examined the expression of p21 mRNA in EBC-1 cells that had been treated with vesnarinone and Dex. Untreated EBC-1 cells expressed a detectable level of p21 mRNA, but this expression was not affected by vesnarinone and/or Dex (data not shown). Similar results were obtained when the expression of p21 protein was analysed by immunoblot. In most NSCLC, p21 protein and RNA were expressed at higher levels than in the corresponding normal tissues, and p21 was expressed independent of changes in p53 gene/protein (Marchetti et al, 1996) . These results suggest that the dephosphorylation of Rb protein by vesnarinone and Dex is independent of the induction of p21 cyclin-dependent kinase inhibitor. Induction of protein phosphatase activity rather than p21 is responsible for chemotherapy-induced Rb dephosphorylation and consequent G 1 arrest in human leukaemia cells (Christoffersen et al, 1994; Dou et al, 1995) . Rb protein phosphatase may be predominantly responsible for p53-independent Rb dephosphorylation, G 1 arrest and apoptosis (Alberts et al, 1993; Ludlow et al, 1993; Christoffersen et al, 1994; Dou et al, 1995) . Preliminary experiments indicate that combined treatment with vesnarinone and Dex induces Rb protein phosphatase activity in EBC-1 cells (data not shown), although we cannot rule out the participation of Rb protein kinase inhibitors other than p21.
Solid tumour cells are generally more resistant to anticancer drugs and apoptosis-inducing agents than leukaemia cells. However, the growth-inhibitory effects of vesnarinone were more prominent in solid tumour cells than in leukaemia cells (Sato et al, 1995 (Sato et al, , 1996 . The actions of many anticancer drugs are mediated by the induction of p53 and/or p21, but the growth-inhibitory effects of vesnarinone on EBC-1 cells were independent of p21. Since many lung cancer cells have an impaired p53/p21-signalling system, a p53/p21-independent mechanism would be important for regulating the abnormal growth of lung cancer cells.
Transforming growth factor (TGF)-β inhibits the growth and induces differentiation of several lung and other carcinoma cells (Twardzik et al, 1989; Chakrabarty et al, 1990; Schroy et al, 1990) . Glucocorticoids synergistically inhibit the growth of monocytoid leukaemia cells in combination with a low concentration of TGF-β (Kanatani et al, 1996) . Vesnarinone, like TGF-β, induces the differentiation of human erythroleukaemia HEL cells (Sato et al, 1996) . However, TGF-β production was not induced by vesnarinone and/or Dex in EBC-1 cells, and TGF-β did not have a synergistic effect with Dex in the growth inhibition of EBC-1 cells (data not shown). These results suggest that TGF-β is not involved in the growth inhibition of EBC-1 cells by Dex and vesnarinone.
Vesnarinone and glucocorticoids are non-genotoxic, and clinically available. Vesnarinone has been approved for use as a cardiotonic drug. The serum level of vesnarinone can be obtained up to 30 µg ml -1 (Miyamoto and Sasabe, 1984; Taira et al, 1984) . There is no appreciable toxicity of vesnarinone on oral administration, since absorption of the drug is saturated due to the low solubility. On rare occasion granulocytopenia (less than 2%) was observed by vesnarinone in humans, but it is reversible when the administration is stopped. Therapy with glucocorticoids or vesnarinone alone may be effective in only a very limited number of cases of NSCLC, since glucocorticoids only have a marked antiproliferative effect on A549 cells (Jones et al, 1978) . Vesnarinone alone has significant anti-tumour activity against human salivary cancer cells in athymic nude mice (Sato et al, 1995) . In human NSCLC cell lines, vesnarinone only had such a significant effect on LK2 cells. However, the combination of vesnarinone and Dex had a significant anti-proliferative effect on all of the lung cancer cell lines tested, and the anti-proliferative effect in vivo was observed without any significant adverse effects. This may be a promising approach to lung cancer therapy which avoids many of the disadvantages of cytotoxic agents.
